|
Tuesday 13 November 2001 |
| 7:30- 8:30 |
ISPOR RUSSIAN CHAPTER BREAKFAST |
| 7:30- 8:30 |
ISPOR ASIA PACIFIC DELEGATES BREAKFAST |
| 8:30-10:00 |
THIRD PLENARY SESSION
|
| |
“COMMUNICATING
PHARMACOECONOMIC / HEALTH ECONOMIC INFORMATION FOR FORMULARY AND REIMBURSEMENT
DECISIONS: OVERCOMING CREDIBILITY ISSUES”
The use of economic evaluations to assist healthcare decision-makers on
rational purchasing decisions about pharmaceuticals has contributed to the
rapid growth of healthcare economic evaluation publications. The quality of
this economic information, its use (or non-use) in decision-making, and
opportunities/challenges will be discussed from three perspectives.
Opportunities and Challenges of Understanding and Using Pharmacoeconomic/Economic
Information from a Decision-maker's Perspective
Moderator &
Speaker: Claude LePen PhD, Professor of Health Economics,
Universitè Paris-Dauphine, Paris, France.
Opportunities & Challenges of Communicating Pharmacoeconomic
Information to Decision-makers
Speaker: Pierre-Philippe Sagnier MD, MPH
(invited), Vice President, Health Economics and Outcomes Research, Bayer
Pharma, London, UK
Opportunities & Challenges of Communicating Medical Device Economic
Information to
Decision-makers
Speaker:
Dr. Sukh Sanghera, Head, Clinical Research & Health Economics, Smith &
Nephew Group Research Centre, York, United Kingdom
|
| 10:00-10:15 |
BREAK |
| 10:15-10:15 |
CONTRIBUTED PODIUM PRESENTATIONS - SESSION III
(4 Concurrent Topics) |
|
DIABETES |
| DB1 |
| ESTIMATING HEALTH CARE-COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS USING DATA FROM THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS)
Gray A, Clarke P, University of Oxford, Oxford, UK |
| DB2 |
| BOTTOM UP VERSUS TOP DOWN COST ESTIMATES FOR TYPE 2 DIABETES
Koopmanschap MA, Redekop K, Niessen L Erasmus University, Rotterdam, Netherlands |
| DB3 |
| A DYNAMIC, THREE-PART MODEL FOR PREDICTING HOSPITAL COSTS IN TYPE 2 DIABETIC PATIENTS
Wang J, Morris A, Davey P, MEMO, University of Dundee, Dundee, UK |
|
|
INFECTIOUS DISEASE |
| IN1 |
| ESTIMATING THE POTENTIAL HEALTH GAIN AND COST CONSEQUENCES OF INTRODUCING A PRE-SCHOOL DTPA PERTUSSIS BOOSTER INTO THE UK CHILD VACCINATION SCHEDULE
Stevenson M1, Beard S1, Finn A2, Brennan A1, 1University of Sheffield, Sheffield, UK; 2University of Bristol, Sheffield, UK |
| IN2 |
| THE ECONOMIC BURDEN OF VIRAL RESPIRATORY INFECTION IN THE UNITED STATES
Fendrick AM1, Sarnes MW2, Nightengale B2, Monto AS1, 1University of Michigan, Ann Arbor, MI, USA; 2Applied Health Outcomes, Tampa, FL, USA |
| IN3 |
| THE OBSERVED COSTS AND HEALTH-CARE USE OF CHILDREN IN A RANDOMIZED CONTROLLED TRIAL OF PNEUMOCOCCAL CONJUGATE VACCINE
Ray GT1, Butler JC2, Black SB1, Sheinfield HR1, Lieu TA3, 1Kaiser Permanente, Oakland, CA, USA; 2Centers for Disease Control and Prevention, Anchorage, AK, USA; 3Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA, USA |
|
|
MENTAL HEALTH I |
| MH1 |
| SOAP-51: A QUALITY OF LIFE SURVEY FOR COMMUNITY-RESIDING INDIVIDUALS WITH SCHIZOPHRENIA
Barr JT1, Schumacher GE1, Mason E1, Ohman S1, Hanson A2, 1Northeastern University, Boston, MA, USA; 2Division of Medical Assistance, Boston, MA, USA |
| MH2 |
| EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE
Hunkeler EM1, Meresman JF2, Hargreaves WA3, 1Kaiser Permanente, Oakland, CA, USA; 2Kaiser Permanente, Northern California, Santa Clara, CA, USA; 3University of California, San Francisco, San Francisco, CA, USA |
| MH3 |
| RECENT WEIGHT GAIN AND THE COST OF ACUTE SERVICE USE AMONG INDIVIDUALS WITH SCHIZOPHRENIA
Weiden PJ1, Mackell JA2, McDonnell DD3, 1SUNY Health Sciences Center at Brooklyn, Brooklyn, NY, USA; 2Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 3Consumer Health Sciences, Princeton, NJ, USA |
|
|
QUALITY OF LIFE |
| QL1 |
| CAN HEALTH STATE VALUES BE PREDICTED FROM HEALTH-RELATED QUALITY OF LIFE MEASURES?
Svensson K1, Szende A2, Lundbäck B3, 1AstraZeneca R&D, Lund, Sweden, 2AstraZeneca, Torokbalint, Hungary, 3University Hospital, Umea, Sweden |
| QL2 |
| ESTIMATING PATIENTS' PREFERENCES IN TREATMENT CHOICES INVOLVING RISK: A NEW MODIFIED STANDARD GAMBLE METHOD
Walshe R, University of Cologne, Cologne, Germany |
| QL3 |
| PSYCHOMETRIC PERFORMANCE OF THE MEDICAL OUTCOMES STUDY SLEEP SCALE IN THE US GENERAL POPULATION
Hays RD1, Martin SA2, Sesti AM2, Spritzer KL1, 1UCLA, Los Angeles, CA, USA; 2Pfizer, Ann Arbor, MI, USA |
|
| 11:15-11:30 |
BREAK |
| 11:30-12:30 |
CONTRIBUTED PODIUM PRESENTATIONS - SESSION IV (4 Concurrent Topics) |
|
MENTAL HEALTH II |
| MH4 |
| SLEEP DISORDERS AND HEALTH RELATED QUALITY OF LIFE - AN EPIDEMIOLOGICAL SURVEY
Isacson D, Bingefors K, Uppsala University, Uppsala, Sweden |
| MH5 |
| COST OF THE FIRST, SECOND AND SUBSEQUENT EPISODE OF DEPRESSION IN POLAND
Kiejna A1, Czech M2, Faluta T2, Pachocki R2, Corcaud S3, 1Medical Academy of Wroclaw, Wroclaw, Poland; 2Servier Polska, Warsaw, Poland; 3Les Laboratoires Servier, Neuilly sur Seine Cedex, France |
| MH6 |
| MODELLING THE COSTS OF ILLNESS AND THE COSTS OF RELAPSE IN THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK
Launois R1, Présenté G1, Hansen K2, Toumi M3, 1REES France, PARIS, France; 2Lundbeck, PARIS, France; 3Lundbeck SA, Paris, France |
|
|
NEUROLOGICAL DISORDERS |
| ND1 |
| INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES
Mychaskiw MA, Thomas III J, Purdue University, West Lafayette, IN, USA |
| ND2 |
| ASSESSING THE QUALITY OF LIFE IN PARKINSON'S DISEASE
Spottke AE1, Reuter M1, Smala A2, Berger K2, Athen O3, Köhne-Volland R3, Meyer D3, Oertel WH2, Dodel RC1, 1Philipps-University Marburg, Marburg, Germany; 2MERG - Medical Economics Research Group, Munich, Germany; 3Metronomia, Munich, Germany |
| ND3 |
| COST-EFFECTIVENESS OF CABERGOLINE COMPARED TO LEVODOPA IN EARLY PARKINSON'S DISEASE IN SWEDEN
Lindgren P1, Jönsson B2, 1Stockholm Health Economics Consulting, Uppsala, Sweden; 2Stockholm School of Economics, Stockholm, Sweden |
|
|
POPULATION COST & HEALTH ISSUES |
| CH1 |
| DEVELOPMENT OF A MINIMUM DATASET (MDS)-BASED COMORBIDITY INDEX FOR A NURSING HOME POPULATION
Gilsenan A, RTI Health Solutions, Research Triangle Park, NC, USA |
| CH2 |
| TRANSITION IN HEALTH-RELATED QUALITY OF LIFE IN U.S. ELDERLY
Zhang JX, The Chinese University of Hong Kong, Shatin, Hong Kong |
| CH3 |
| TRENDS IN POPULATION-BASED HEALTH-RELATED QUALITY OF LIFE: IMPLICATIONS FOR INTERPRETATION OF CHANGE
Erickson P, Pennsylvania State University, State College, PA, USA |
|
|
RESPIRATORY DISEASE/DISORDERS |
| RP1 |
| DOES ILLNESS-RELATED LOST PRODUCTIVE WORK TIME VARY BY JOB DEMAND OR JOB CONTROL: A CASE STUDY OF ALLERGIC RHINITIS (AR)
Stewart WF, Ricci J, Leotta CR, Chee E AdvancePCS, Hunt Valley, MD, USA |
| RP2 |
| THE NET COST OF ASTHMA TO A US PUBLIC MEDICAID PROGRAM
Pannicker S1, Nielsen K2, Martin BC1, 1University of Georigia, Athens, GA, USA; 2GlaxoSmithKline, RTP, NC, USA |
| RP3 |
| PREPARING THE ASTHMA SYMPTOM UTILITY INDEX FOR INTERNATIONAL USE: TRANSLATION AND LINGUISTIC VALIDATION
Flood EM1, Eremenco SL2, Schmier JK1, Mörk AC3, Stahl E3, Arnold B2, Hudgens S2, Leidy NK1, 1MEDTAP International, Inc, Bethesda, MD, USA; 2Evanston Northwestern Healthcare, Evanston, IL, USA; 3AstraZeneca R&D, Lund, Sweden |
|
| 12:30-13:30 |
LUNCH, EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS - SESSION II |
| 14:00- 15:00 |
CONTRIBUTED WORKSHOP PRESENTATIONS - SESSION III (6 Concurrent Workshops) |
| WW15 |
|
IMPLEMENTING THE UK NICE CONCEPT IN ANOTHER EUROPEAN COUNTRY: NICE TRY OR "SALADE NICOISE"?
Annemans LJ1, Robays H2, Peys F3, 1Ghent University, HEDM, MEISE, Belgium; 2Ghent University Hospital, GENT, Belgium; 3BIGE, Zaventem, Belgium |
| WW16 |
|
ASSESSING PHARMACOECONOMIC AND QUALITY OF LIFE OUTCOMES IN GLOBAL PATIENT REGISTRIES
Marle C1, Brod M2, Peeters P1, Sullivan EM3, 1Quintiles Late Phase, Levallois-Perret, France; 2Quintiles Late Phase, San Francisco, CA, USA; 3Quintiles Late Phase, Boston, MA, USA |
| WW17 |
|
COST OF ILLNESS STUDIES: DO WE STILL NEED THEM?
Chambers MG1, Hutton J2, Nuijten MJ3, 1MEDTAP International, London, UK; 2MEDTAP International, Inc, London, UK; 3MEDTAP International, Jisp, Netherlands |
| WW18 |
|
FATIGUE ASSESSMENT AS AN OUTCOME IN CANCER CLINICAL TRIALS
Bottomley A, Flechtner H, On behalf of the EORTC Quality of Life Group, Brussels, Belgium |
| WW19 |
|
MEASURES AND METHODS FOR ASSESSING PATIENT-REPORTED OUTCOMES
Duffer AP, Fehnel SE, RTI Health Solutions, Research Triangle Park, NC, USA |
| WW20 |
|
ITEM RESPONSE THEORY AND ITS APPLICATIONS TO HEALTH OUTCOMES MEASUREMENT
Chang C-H, Cella D, Evanston Northwestern Healthcare and Northwestern University, Evanston, IL, USA |
|
| 14:30-14:45 |
BREAK |
| 14:45-15:45 |
CONTRIBUTED WORKSHOP PRESENTATIONS - SESSION IV (6 Concurrent Workshops) |
| WW21 |
|
MAXIMIZING THE SCIENTIFIC AND STRATEGIC VALUE OF PATIENT REGISTRIES
Trotter J, Larson L, Vreeland MG, Ovation Research Group, Highland Park, IL, USA |
| WW22 |
|
HEALTHCARE DATABASE AS A SERVICE CONTRACTING TOOL - BETWEEN INFORMATION DESERT AND INFORMATION FLOOD: EXPERIENCE OF POLISH HEALTH CARE SYSTEM REFORM
Sosnierz A, Jendroszczyk J, Makselon-Jarzabek A, Silesian Regional Sickness Fund, Katowice, Poland |
| WW23 |
|
INCONGRUITY BETWEEN THE USE OF HEALTH ECONOMIC ANALYIS AND BUDGETARY IMPACT ANALYSIS
Hutton J1, Engelfriet P2, Brown R1, Nuijten M2, 1Medtap International, London, England; 2Medtap International, Jisp, Netherlands |
| WW24 |
|
USING PROPENSITY SCORES TO ADJUST FOR TREATMENT SELECTION BIAS: REVIEW OF METHODS PLUS AN EXTENSION FOR USE IN STUDIES WITH THREE OR MORE TREATMENT GROUPS
Irish W, Neighbors D, Lopez R, RTI Health Solutions, Research Triangle Park, NC, USA |
| WW25 |
|
HEALTH-RELATED QUALITY OF LIFE MEASUREMENT: A SYSTEMATIC APPROACH TO SELECTING AN ASSESSMENT STRATEGY
Erickson P, PSU and The On-Line Guide to Quality-of-Life Assessment (OLGA), State College, PA, USA |
| WW26 |
|
METHODOLOGICAL ISSUES OF DESIGNING QUALITY OF LIFE IN CANCER CLINICAL TRIALS
Bottomley A, Flechtner H, On behalf of the EORTC Quality of Life Group, Brussels, Belgium |
|
|
